Amarin Provides 2009 Year-End Review to Shareholders

Thursday, January 28, 2010 Corporate News
Email Print This Page Comment
Font : A-A+

New investors and experienced new team focused on driving Phase 3 clinical development of AMR101 for cardiovascular diseases

Contacts:

Investor Contact Information:

John F. Thero

Chief Financial Officer

In US: +1 (860) 572 4979

investor.relations@amarincorp.com

Gitanjali Ogawa

The Trout Group

In U.S. +1 (646) 378-2949

gogawa@troutgroup.com

International Media Contact Information:

Mark Swallow or David Dible

Citigate Dewe Rogerson

In UK: +44 (0)207 638 9571

mark.swallow@citigatedr.co.uk



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook